BibTex format
@article{Smith:2024:10.1038/s41591-024-03232-y,
author = {Smith, DRM and Turner, J and Fahr, P and Attfield, LA and Bessell, PR and Donnelly, CA and Gibb, R and Jones, KE and Redding, DW and Asogun, D and Ayodeji, OO and Azuogu, BN and Fischer, WA and Jan, K and Olayinka, AT and Wohl, DA and Torkelson, AA and Dinkel, KA and Nixon, EJ and Pouwels, KB and Hollingsworth, TD},
doi = {10.1038/s41591-024-03232-y},
journal = {Nat Med},
title = {Health and economic impacts of Lassa vaccination campaigns in West Africa.},
url = {http://dx.doi.org/10.1038/s41591-024-03232-y},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of 'Lassa-X'-a hypothetical pandemic Lassa virus variant-and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7 million (95% uncertainty interval: 2.1-3.4 million) Lassa virus infections annually, resulting over 10 years in 2.0 million (793,800-3.9 million) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified 'endemic' districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1 million ($8.2-$39.0 million) in lost DALY value and $128.2 million ($67.2-$231.9 million) in societal costs (2021 international dollars ($)). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2 million DALYs within 2 years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever's burden and assist in pandemic preparedness.
AU - Smith,DRM
AU - Turner,J
AU - Fahr,P
AU - Attfield,LA
AU - Bessell,PR
AU - Donnelly,CA
AU - Gibb,R
AU - Jones,KE
AU - Redding,DW
AU - Asogun,D
AU - Ayodeji,OO
AU - Azuogu,BN
AU - Fischer,WA
AU - Jan,K
AU - Olayinka,AT
AU - Wohl,DA
AU - Torkelson,AA
AU - Dinkel,KA
AU - Nixon,EJ
AU - Pouwels,KB
AU - Hollingsworth,TD
DO - 10.1038/s41591-024-03232-y
PY - 2024///
TI - Health and economic impacts of Lassa vaccination campaigns in West Africa.
T2 - Nat Med
UR - http://dx.doi.org/10.1038/s41591-024-03232-y
UR - https://www.ncbi.nlm.nih.gov/pubmed/39198710
ER -